Red Yeast Rice with CoQ10, 600mg
Food supplement declared in France, decision dated 15 April 2026
Red Yeast Rice with CoQ10, 600mg (NOW Foods) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: acide lipoïque 100 mg per day, Silybum marianum 210 mg per day, Monascus purpureus 2.1 g per day, Ubiquinone. 1 rule of use applies to its ingredients (limits and warnings).
- Brand
- NOW Foods
- Food business operator placing the product on the market
- Olivit Sp. z o.o.
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 2 gélules
- Intended populations
- Men and women aged 18 and over
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Pregnant women, Taking medication, Children (under 10)
- Objectives stated by the manufacturer (these are not authorised claims)
- Arteries and cholesterol
Declaration 362434, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Silybum marianum (L.) Gaertn. | Fruit | Extrait sec hydroalcoolique | 210 mg |
| Monascus purpureus Went | Plante entière | Extrait sec hydroalcoolique | 2.1 g |
Substances
| Name | Per day |
|---|---|
| acide lipoïque | 100 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Ubiquinone | not declared |
Additives
E551, E570, E460
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Regulatory points
- Conditions légales
Contains red yeast rice. Monacolins must remain below 3 mg per daily portion, with mandatory warnings on the label. The monacolin content is not declared in Compl'Alim.
Source: Regulation (EC) No 1925/2006, latest consolidated version, annexe III, partie B (règlement (UE) 2022/860).
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Silybum marianum (L.) Gaertn.
Read the warning, when it applies and the studies cited
MILK THISTLE - SILYBUM MARIANUM
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Brinker 2010; Mills et al. 2006).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills E, Dugoua J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation : An Evidence-Based Approach. London (UK): Taylor and Francis Medical; 2006.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Geier et al. 1990; Mironets et al. 1990).
Sources cited by Health Canada (2)
- Geier J, Fuchs Th, Wahl R. [Anaphylactic shock due to an extract of Silybum marianum in a patient with immediate-type allergy to Kiwi fruit]. Anaphylaktischer Schock durch einen Mariendistel-Extrakt bei Soforttyp-Allergie auf Kiwi. Allergologie 1990;13(10):387-388 (in German).
- Mironets VI, Krasovskaia EA, Polischuk II. [A case of urticaria during carsil treatment]. Vrachebnoe Delo 1990;(7):86-87 (in Russian).
- acide lipoïque
Read the warning, when it applies and the studies cited
DL-ALPHA-LIPOIC ACID/R-ALPHA-LIPOIC ACID
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Jacob et al. 1999, Konrad et al. 1999, Packer et al. 1995).
Sources cited by Health Canada (3)
- Jacob S, Ruus P, Hermann R, Tritschler HJ, Maerker E, Renn W, Augustin HJ, Dietze GJ, Rett K. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radical Biology & Medicine 1999;27(3-4):309-314. PubMed Randomised trial
- Konrad T, Vicini P, Kusterer K, Höflich A, Assadkhani A, Böhles HJ, Sewell A, Tritschler HJ, Cobelli C, Usadel KH. Alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care 1999;22(2):280-287. PubMed
- Packer L, Witt EH, Tritschler HJ. Alpha-Lipoic acid as a biological antioxidant. Free Radical Biology & Medicine 1995;19(2):227-250. PubMed Review article
Applies to products providing 42 milligrams or more DL-alpha-lipoic acid or 21 milligrams or more R-alpha-lipoic acid, per day.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience sweating, paleness, chills, headache, dizziness and/or confusion (as these may be symptoms of serious low blood sugar) (Bae et al., 2013; Gullo et al., 2014; Bresciani et al., 2011; Chang et al., 2009).
Sources cited by Health Canada (4)
- Bae SM, Bae MN, Kim EY, Kim IK, Seo MW, Shin JK, Cho SR, Jeong GH. Recurrent Insulin Autoimmune Syndrome Caused by α-Lipoic Acid in Type 2 Diabetes. Endocrinol Metab (Seoul). 2013;28(4):326-330. PubMed
- Bresciani E, Bussi A, Bazzigaluppi E, Balestrieri G. Insulin autoimmune syndrome induced by α-lipoic acid in a Caucasian woman: case report. Diabetes Care. 2011 Sep;34(9):e146. doi: 10.2337/dc11-0600. DOI
- Chang HJ, Choi HS, Park MY, Leem SM, Jang YS, Park KS, Lee JM. A case of insulin autoimmune syndrome related to alpha-lipoic acid. Korean J Med 2009;76:600-604.
- Gullo D, Evans JL, Sortino G, Ira D. Goldfine and Vigneri R. Insulin autoimmune syndrome (Hirata Disease) in European Caucasians taking a-lipoic acid. Clinical Endocrinology 2014;81: 204-209. PubMed
- Ubiquinone
Read the warning, when it applies and the studies cited
Coenzyme Q10 (UBIQUINONE-10)
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).
Sources cited by Health Canada (2)
- Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
- Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial
Applies to products providing more than 100 mg of Coenzyme Q10 per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (3)
- Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Condition of application: Migraine prophylaxis/prevention.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Brand : NOW Foods
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Red Yeast Rice with CoQ10, 600mg (NOW Foods): composition and regulation”, https://compoatlas.com/en/supplements/products/362434-red-yeast-rice-with-coq10-600mg, updated 15 November 2026.